Nginache Nampota Nkomba
@NginacheVN
Doctor. Clinical researcher. Vaccine and drug development scientist. Epidemiologist. PhD student. Tackling disease through generation of high quality evidence!
Tomorrow! 📣 Dr. Matt Laurens (@laurens_matt), Professor of Pediatrics, Medicine and Pathology at @UMmedschool and Project Director of TyVAC, joins host Ngina Nampota-Nkomba (@NginacheVN) for a new episode of our discussion series, Getting to Zero! The conversation will cover…
Be sure to tune in!
Dr. Matt Laurens (@laurens_matt), Professor of Pediatrics, Medicine and Pathology at @UMmedschool and Project Director of TyVAC, joins host Ngina Nampota-Nkomba (@NginacheVN) for a new episode of our discussion series, Getting to Zero! Tune in for essential insights on: 🌍 The…
Excited to host @sabinvaccine’s ‘Getting to Zero’ series - join me as I talk to global health leaders about the path to eliminating vaccine preventable disease! #GettingToZero #GlobalHealth
📣 We're so excited that our 2021 Rising Star Nginache Nampota-Nkomba (@NginacheVN) is joining our discussion series, Getting to Zero, as a host for Season 2! She'll be talking to leading global health experts about what it will take to eliminate vaccine-preventable diseases.…
Honored to receive the Patricia Langenberg Endowment in Epidemiology & Women’s Health Award at the @UMBGradSchool. I am grateful for this recognition and the support it provides toward my research journey. #PhDLife #Epidemiology #PublicHealth #WomenInSTEM
HPV vaccination for boys in LMICs is urgent! In a cohort of 498 circumcised SMM in Nigeria: 🔹72.7% had penile HPV 🔹48.0% were high-risk strains 🔹HIV ↑ odds of penile HPV (aOR 1.93) 🔹Most prevalent HPV types (16, 51, 45, 18) are vaccine-preventable. pubmed.ncbi.nlm.nih.gov/40239119/
🚨 Even with ART use, HIV still affects birth outcomes. 💡 But...viral suppression mitigates this risk! Women with well-controlled HIV had better birth outcomes, including lower risk of low birth weight in our cohort of Malawian women. Read more here: journals.lww.com/jaids/abstract…
So excited to have attended #ESCMIDGlobal for the first time! I gave a talk on #typhoid #vaccine roll-out in a session on introducing vaccines in low-resource settings. The discussion format made for an engaging and thought-provoking exchange. #TakeOnTyphoid @PreventTyphoid
Coming soon! 📣 Season 2 of our Getting to Zero discussion series with episodes hosted by Sabin Rising Star winners Sangwe Clovis Nchinjoh (@TheRuralDtor), Nginache Nampota-Nkomba (@NginacheVN), and Nicole E. Basta (@IDEpiPhD) Join their interviews with immunization leaders from…
📢 March issue now online featuring #rotavirus, #typhoid, #lungcancer, bipolar disorder, #AF, elective cesarean section, and much more with our editorial on the measles outbreak in the USA …all available #OpenAccess❗️ Read more here: thelancet.com/issue/S2589-53… Attribution: Getty
Exciting new data on #TyphoidConjugateVaccines! ✅ Sustained immunity 4 years post-vaccination (given at 9-11 months) ✅ Strong booster response at 5 years old These data are key for policy decisions. Read more: sciencedirect.com/science/articl…
A new study in #Malawi—the first to evaluate long-term immunogenicity of #typhoid conjugate vaccines (TCV) in #Africa—can help inform decision-makers on how to prioritize TCV introduction. Read more⬇️ coalitionagainsttyphoid.org/robust-immune-… #TakeOnTyphoid @NginacheVN @UMCVD @MLW_Programme
Looking for candidates for Master’s and PhD. scholarship opportunities! Fields include Control Science & Engineering, Electrical Engineering, Civil Engineering, Hydraulic Engineering, Geological Sciences & Engineering, or Management Sciences & Engineering.
On day 2 at @ASTMH I got to share our data on one and two dose, as well as booster dose typhoid conjugate vaccine immunogenicity from Malawi. It was a great discussion. #TakeOnTyphoid #TropMed24 @PriyaDPatel5 @OswardNyirenda @ttmalawi
Spotted at @ASTMH 👋 @NginacheVN gives her presentation, "One and two dose #typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and #HIV unexposed uninfected Malawian children." #TropMed24 Full schedule of events available online ⤵️…
Day 1 @ASTMH . Excited to learn from other researchers in tropical medicine and looking forward to sharing some of the work I’ve been doing too! #IamTropMed #TropMed24
Our new study on typhoid conjugate vaccines in Malawi shows a single dose of TCV is safe & produces a robust immune response in HIV-exposed and HIV-unexposed children. This is a big step toward protecting children in HIV endemic regions. #TakeonTyphoid ncbi.nlm.nih.gov/pmc/articles/P…
Researchers found that #typhoid conjugate vaccines are safe and well tolerated in children exposed to #HIV, which means these children can follow the routine immunization schedule in their country. #VaccinesWork coalitionagainsttyphoid.org/typhoid-conjug…
📰 In the latest #TakeOnTyphoid newsletter, updates on: ➡️ #Typhoid vaccinations in #Pakistan ➡️ Financial costs of typhoid for families & hospitals ➡️ A new tool to track drug resistance ➡️ Recent accolades of @NginacheVN & @meganecarey ...and more! coalitionagainsttyphoid.org/take-on-typhoi…
Congratulations @NginacheVN for receiving the 2024 Maurice R. Hilleman Early-Stage Career Investigator Award! Nginache is doing incredible work to #TakeOnTyphoid🙌🏾👏🏼 nfid.org/award/maurice-… @NFIDVaccines